Fewer than 10% of individuals eligible to benefit from weight-loss injections like Wegovy can access them, caution the World Health Organization as it issues its initial recommendations on the medications.
Given in excess of 1,000,000,000 individuals worldwide now classified as obese, it is advocating for more widespread and fairer access to these injectable treatments.
According to estimates, in excess of 2,000,000,000 could be obese by 2030 if no action is taken.
"Our new guidance acknowledges that obesity is a chronic disease that can be addressed with comprehensive and lifelong support," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are significant barriers to widespread access to the jabs that can assist patients in reducing significant body mass, explains the body.
Skinny Jab Scarcity
Even in the current most optimistic outlook, the manufacturing of these medications could only cover about 100 million people – under 10% of eligible patients, per the WHO.
The guideline encourages countries and companies to widen availability, by approaches including voluntary licensing.
A patent on a key compound – the main ingredient of the drug Wegovy – is due to expire in several countries in 2026.
How Weight-Loss Drugs Work
GLP-1 drugs imitate a biological compound to slow digestion, reduce hunger and enhance feelings of fullness so individuals reduce food intake.
Individuals commonly see weight reduction in the initial weeks of commencing the weekly injections.
Research indicates patients may regain a significant portion within a year of stopping the medication, when their usual hunger resume.
Being above a healthy weight raises your likelihood for contracting health problems, like diabetes, cardiovascular issues, stroke, and some cancers.
Obesity concerns individuals in every country and was associated with over three and a half million deaths worldwide in 2024, as per the WHO.
